1. Scrip
  2. >>COVID-19

BIO 2021 Notebook: Looking Past The Pandemic

Annual Meeting Focuses On Post-COVID R&D, Politics And New Opportunities

 
• By Scrip Team and Pink Sheet Team

News and views from day one of the BIO Digital annual meeting include debate about when FDA will go back to the offices, industry's role in pandemic-related policy discussions and how to prepare for the next pandemic. 

BIO 2021 Notebook - Day 1

The COVID-19 pandemic changed the conversation about the biopharma industry from pricing, reimbursement and affordability to “how could we save the world,” Cerevel Therapeutics Holdings, Inc. CEO Tony Coles said during a 14 June fireside chat on the opening day of the Biotechnology Innovation Organization annual meeting.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.